AREEP Alexandria Real Estate Equities Inc featured news, full reports, and detailed charts
Alexandria Real Estate Equities Inc (AREEP/AREEP.PK) Wrap Up:
Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. Its properties consist of buildings containing scientific research and development laboratories, and other improvements. The company offers its properties for lease primarily to universities and independent not-for-profit institutions; and pharmaceutical, biotechnology, medical device, life science product, service, biodefense, and translational research entities, as well as governmental agencies. As of December 31, 2006, it had 159 properties, including 156 properties located in 9 states in the United States and 3 properties located in Canada. As a REIT, the company is not subject to federal income tax to the extent that it distributes 100% of its taxable income to its stockholders. The company was founded in 1993 and is based in Pasadena, California.Alexandria Real Estate Equities Inc (AREEP:OTC)
|
Market Cap
2.5B
|
Total Revenue
499.3M
|
|
|
EBITDA
328.0M
|
DILUTED EPS TTM
3.06
|
|
|
P/E
18.7x
|
P/S
4.5x
|
|
|
Return On Asset
2.69
|
Return On Equity
6.83
|
|
| K = Thousands M = Millions B = Billions | ||
related news
AREEP Top Compensated Officers
Executives, Board Directors
Key developments for Alexandria Real Estate Equities Inc (AREEP)
Alexandria Real Estate Equities Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net income attributable to the company's common stockholders of $18.2 million or $0.47 per basic and diluted share on total revenues of $114.6 million, income from continuing operations of $25.2 million or $0.44 per basic and diluted share compared to net income attributable to the company's common stockholders of $19.3 million or $0.61 per basic and diluted share on total revenues of $112.5 million, income from continuing operations of $26.6 million or $0.58 per basic and diluted share a year ago. Funds from operations (FFO) attributable to the company's common stockholders was $50.6 million or $1.13 per diluted share compared to FFO attributable to the company's common stockholders of $46.27 million or $1.45 per diluted share for the third quarter of 2008. For the nine months, the company reported net income attributable to the company's common stockholders of $83.3 million or $2.26 per basic and diluted share on total revenues of $365.7 million, income from continuing operations of $108.02 million or $2.16 per basic and diluted share compared to net income attributable to the company's common stockholders of $71.5 million or $2.25 per diluted share on total revenues of $327.1 million, income from continuing operations of $74.07 million or $1.68 per basic and diluted share a year ago. FFO attributable to the company's common stockholders was $180.42 million, or $4.49 per diluted share compared to FFO attributable to the company's common stockholders of $130.31 million, or $4.11 per diluted share for nine months ended September 30, 2008. For the year 2009, the company expects that FFO per diluted share attributable to the company's common stockholders of $5.52 and earnings per diluted share attributable to the company's common stockholders of $2.69.
Alexandria Real Estate Equities Inc. expected to Report Fiscal Year 2009 Results on February 10, 2010. This event was calculated by Capital IQ (Created on October 29, 2009).
Alexandria Real Estate Equities, Inc. provided an update highlighting recent accomplishments. Alexandria announced the delivery of a state-of-the-art facility to Pfizer Inc. at the Alexandria Center for Science and Technology at Mission Bay. As announced in August, 2008, Pfizer Inc. entered into a 15-year lease for approximately 102,000 square feet at this dynamic, first-in-class life science cluster. Alexandria's highly skilled development and construction teams worked closely with Pfizer Inc. to develop a robust, flexible and reusable base building with state-of-the-art infrastructure. "We are proud to have worked closely with Pfizer on the design and construction of this state-of-the-art facility. Equally important, we are pleased to note that the building was delivered on time and on budget," said Stephen Richardson, Senior Vice President and Regional Market Director for the San Francisco Bay Area, Alexandria Real Estate Equities, Inc. Also, as part of the ongoing execution of Alexandria's multi-faceted capital plan, Alexandria reported the identification of four properties for sale aggregating approximately 269,000 rentable square feet, including several properties that are under negotiation for sale. These properties will be sold primarily to life science users with anticipated closings over the next several quarters. Total estimated sales prices for these properties, including the three properties that have been sold to date in 2009, aggregate approximately $50 million. The proceeds of these asset sales have and will be used to repay outstanding indebtedness on Alexandria's unsecured revolving line of credit.
AREEP Competitors
| Company | Last | Change | |
| No competitor information is available for AREEP. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | AREEP | Industry Range |
| Price/Earnings | 18.7x |
|
| Price/Sales | 4.5x |
|
| Price/Book | 1.3x |
|
| Price/Cash Flow | 9.9x |
|
| TEV/Sales | NM | Not Meaningful |
|
AREEP |
||
AREEP transactions
| Type Date |
Target |
|
Private Placement
August 21, 2009 |
Cambrios Technologies Corp. |
